NIH begins clinical trial of hydroxychloroquine and azithromycin to treat COVID-19

(NIH/National Institute of Allergy and Infectious Diseases) A clinical trial has begun to evaluate whether the malaria drug hydroxychloroquine, given together with the antibiotic azithromycin, can prevent hospitalization and death from coronavirus disease 2019 (COVID-19). The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the trial, which is being conducted by the NIAID-funded AIDS Clinical Trials Group (ACTG). Teva Pharmaceuticals is donating medications for the study.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news